| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 5g | |||
| Other Sizes |
Purity: ≥98%
Atovaquone (also called atavaquone) is a hydroxynaphthoquinone based antiprotozoal and antimicrobial medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia. Atovaquone is a chemical compound that belongs to the class of naphthalenes. Atovaquone is a hydroxy-1,4-naphthoquinone, an analog of ubiquinone, with antipneumocystic activity. Atovaquone is an anti-protozoal mitochondrial electron transport inhibitor; Antimalarial; Antipneumocystic, and has also been used to treat toxoplasmosis. It acts by inhibiting the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket.
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
Am J Trop Med Hyg.1996 Jan;54(1):62-6;J Biol Chem.2003 Aug 15;278(33):31312-8;Antimicrob Agents Chemother. 2002 May; 46(5): 1163–1173.
|
||
| Additional Infomation |
Atovaquone is a naphthoquinone compound with a 4-(4-chlorophenyl)cyclohexyl group at position 2 and a hydroxyl substituent at position 3. It exhibits various activities including antimalarial activity, antifungal activity, inhibition of dihydroorotate dehydrogenase (quinone) activity, inhibition of NADH/ubiquinone reductase (H(+)- transporter) activity, and inhibition of quinone cytochrome c reductase activity. It belongs to the monochlorobenzene class of compounds and is a hydroxy-1,4-naphthoquinone. Atorvaquinone is an antimalarial and antiseptic drug. It is a hydroxynaphthoquinone with antibacterial activity and is currently used in antimalarial treatment regimens. See also: Atorvaquinone (note moved to).
|
| Molecular Formula |
C22H19CLO3
|
|---|---|
| Molecular Weight |
366.84
|
| Exact Mass |
366.102
|
| Elemental Analysis |
C, 72.03; H, 5.22; Cl, 9.66; O, 13.08
|
| CAS # |
95233-18-4
|
| Related CAS # |
Atovaquone-d4;2070015-14-2;Atovaquone-d5;1329792-63-3;cis-Atovaquone-d4
|
| PubChem CID |
74989
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
542.2±50.0 °C at 760 mmHg
|
| Melting Point |
216-2190C
|
| Flash Point |
281.7±30.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.653
|
| LogP |
5.86
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
26
|
| Complexity |
595
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C2C=CC=CC=2C(=O)C(O)=C1[C@@H]1CC[C@@H](C2C=CC(Cl)=CC=2)CC1
|
| InChi Key |
KUCQYCKVKVOKAY-CTYIDZIISA-N
|
| InChi Code |
InChI=1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,26H,5-8H2/t13-,15-
|
| Chemical Name |
trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione
|
| Synonyms |
566C; 566C80; 566C80 hydroxynaphthoquinone; 566C80, hydroxynaphthoquinone; Atovaquone; atovaquone GlaxoSmithKline brand; compound 566; Glaxo Wellcome brand of atovaquone; GlaxoSmithKline brand of atovaquone; hydroxynaphthoquinone 566C80; hydroxynaphthoquinone, 566C80; Mepron; Wellvone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :8.33 ~ 11 mg/mL ( 22.71 ~29.98 mM )
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 0.83 mg/mL (2.26 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.83 mg/mL (2.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 5% DMSO + Corn oil: 0.5mg/ml (1.36mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7260 mL | 13.6299 mL | 27.2598 mL | |
| 5 mM | 0.5452 mL | 2.7260 mL | 5.4520 mL | |
| 10 mM | 0.2726 mL | 1.3630 mL | 2.7260 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT03568994
Conditions:Acute Myeloid LeukemiaLink: https://clinicaltrials.gov/ct2/show/NCT07357103
Conditions:Pneumocystis|Pneumocystis Infection|Pneumocystis Carinii Infection|Pneumocystis Carinii; Infection, Resulting From HIV Disease|Pneumocystis Jirovecii Pneumonia|Pneumocystis Jirovecii Infection|Pneumocystosis Associated With AIDS|Pneumocystosis; Pneumonia (Etiology)Link: https://clinicaltrials.gov/ct2/show/NCT05998135
Conditions:Ovarian High Grade Serous Adenocarcinoma|Platinum-Resistant Ovarian Carcinoma
Title:Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Status:Recruiting
updateDate:2025-07-22
Ctid:NCT06624371
Link: https://clinicaltrials.gov/ct2/show/NCT06624371
Conditions:High-grade Glioma|Medulloblastoma|Diffuse Intrinsic Pontine Glioma|Diffuse Midline Glioma, H3 K27M-MutantLink: https://clinicaltrials.gov/ct2/show/NCT00000811
Conditions:Bacterial Infections|Pneumonia, Pneumocystis Carinii|HIV InfectionsLink: https://clinicaltrials.gov/ct2/show/NCT00000802
Conditions:Pneumonia, Pneumocystis Carinii|HIV InfectionsLink: https://clinicaltrials.gov/ct2/show/NCT00000773
Conditions:Pneumonia, Pneumocystis Carinii|HIV InfectionsLink: https://clinicaltrials.gov/ct2/show/NCT00000794
Conditions:Toxoplasmosis, Cerebral|HIV InfectionsLink: https://clinicaltrials.gov/ct2/show/NCT02628080
Conditions:Carcinoma, Non-Small-Cell LungLink: https://clinicaltrials.gov/ct2/show/NCT01858831
Conditions:MalariaLink: https://clinicaltrials.gov/ct2/show/NCT00000655
Conditions:Pneumonia, Pneumocystis Carinii|HIV InfectionsLink: https://clinicaltrials.gov/ct2/show/NCT00001990
Conditions:Pneumonia, Pneumocystis Carinii|HIV InfectionsLink: https://clinicaltrials.gov/ct2/show/NCT00001996
Conditions:Pneumonia, Pneumocystis Carinii|HIV InfectionsLink: https://clinicaltrials.gov/ct2/show/NCT00001991
Conditions:Pneumonia, Pneumocystis Carinii|HIV InfectionsLink: https://clinicaltrials.gov/ct2/show/NCT00001994
Conditions:Toxoplasmosis, Cerebral|HIV InfectionsLink: https://clinicaltrials.gov/ct2/show/NCT00002340
Conditions:Pneumonia, Pneumocystis Carinii|HIV InfectionsProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA